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Abstract 
Glimepiride is a novel sulfonylurea drug for treatment of non-insulin-dependent diabetes mellitus with higher blood sugar 
lowering efficacy in diabetic patients than glibenclamide raising the question whether this characteristics is in line with different 
binding of glimepiride and glibenclamide tothe 0-cell sulfonylurea receptor. Scatchard plot analysis of [3H]sulfonylurea binding 
to membranes i olated from rat 0-cell tumors and (RINm5F) insulinoma cells and to RINm5F cells demonstrated that 
glimepiride has  2.5-3-fold lower affinity than glibenclamide. This corresponded well to the 8-9-fold higher kof and 2.5-3-fold 
higher kon rates of glimepiride compared to glibenclamide as revealed by the dissociation and association kinetics of 
[3H]sulfonylurea binding and the K d values calculated thereof. In agreement, the concentrations required for half-maximal 
displacement of [3H]sulfonylurea bound to 0-cell membranes were significantly higher for glimepiride compared to gliben- 
clamide. However, the binding affinity of glimepiride measured by both equilibrium binding and kinetic binding studies upon 
solubilization of 0-cell tumor membranes and RINm5F cell membranes increased up to the value for glibenclamide. This was 
primarily based on a drastic decrease of the dissociation rate constant of glimepiride whereas the kinetics of glibenclamide 
binding remained largely unaffected upon solubilization. These data suggest hat the K d value alone is not sufficient for 
characterization f a suifonylurea drug, since the kinetic binding parameters may also determine its acute blood sugar lowering 
efficacy. 
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I. Introduction 
Sulfonylurea drugs are widely used in the therapy of 
NIDDM. The initial hypoglycemic effect of oral sul- 
fonylurea administration appears to rely on the acute 
stimulation of-the rate of insulin release from the 
pancreas (Yalow et al. [1]). At the molecular level 
sulfonylureas are proposed to stimulate insulin secre- 
tion by binding to a receptor protein of the plasma 
membrane of pancreatic/3-cells (for reviews, see [2,3]). 
Receptor occupancy has been shown to inhibit K+-ef - 
flux via a plasma membrane ATP-regulated K+-chan - 
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nel in islet cells [4] and E-cell lines such as RINm5F [5] 
or HIT T15 [6]. These channels also participate in the 
control of insulin release by glucose [7] via changes in 
the intracellular [ATP]/[ADP] ratio. Subsequent depo- 
larization of the plasma membrane causes opening of 
voltage-dependent Ca2+-channels. The rise in intra- 
cellular Ca 2÷ triggers insulin release [8,9] (for a review, 
see [10]). This chain of events couples the insulin 
releasing effect and, thus, the primary hypoglycemic 
capacity of sulfonylureas via the plasma membrane 
electrical activity to their affinity to the/3-cell sulfony- 
lurea binding sites which control the open/closed 
probability of the ATP-regulated K+-channel by un- 
known mechanisms. 
Specific high-affinity binding sites (for a recent re- 
view, see Ashcroft and Ashcroft [11]) have been char- 
acterized previously in /3-cell tumor membranes [12- 
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14], RINmSF cell membranes and i tact RINm5F cells 
[15], mouse pancreatic islet microsomes [16], hamster 
insulin-secreting tumor cell (HIT T15) membranes 
[14,17,18] and intact HIT T15 cells [19]. In fact, a direct 
correlation has been found for the sulfonylureas stud- 
ied so far between their dissociation constants for 
binding to/3-cell membranes and their ability to induce 
insulin secretion and to lower the blood sugar [5,13,16]. 
For instance, the second generation sulfonylurea, 
glibenclamide, is a 1000-fold more potent stimulator of 
insulin secretion than first generation compounds such 
as tolbutamide in correlation with the 1000-10 00-fold 
lower K d value of glibenclamide compared to tolbu- 
tamide [5]. Using the receptor occupancy theory, it was 
successful to predict he therapeutic blood concentra- 
tions and usual doses of sulfonylureas, based on the 
good correlation between plasma unbound concentra- 
tion, insulin releasing potency and K d values [20]. 
The novel sulfonylurea drug, glimepiride, is charac- 
terized by a 2-3-fold higher efficacy in diabetic pa- 
tients compared to glibenclamide with respect to equiv- 
alence of the dose ranges leading to identical blood 
sugar levels after oral administration (Draeger, E., 
unpublished results). Here we studied whether glime- 
piride exhibits higher binding affinity to the fl-cell 
sulfonylurea receptor than glibenclamide and found 
that, in contradiction tothis expectation, other (kinetic) 
binding parameters may explain the lower therapeutic 
doses required with glimepiride. 
Parts of the results have been published in abstract 
form: 
Kramer, W., l)konomopulos, R., Piinter, J. and Summ, 
H.-D. (1992) Diabetologia 35 (Suppl. 1), A 38; 
Miiller, G., Hartz, D., Piinter, J., Okonomopulos, R., 
Summ, H.-D. and Kramer, W. (1993) International 
Conference on ATP-sensitive K+-channels and sulfo- 
nylurea receptors, Houston, TX, Book of Abstracts, p. 
158. 
2. Materials and methods 
Materials. Glimepiride (HOE 490), glibenclamide 
(HB 419), tolbutamide, [3H]glimepiride (65 Ci/mmol) 
and [3H]glibenclamide (33 Ci/mmol) were synthesized 
at Hoechst AG, Frankfurt, Germany [13,21]. A 10 mM 
stock solution of glimepiride (made daily) was pre- 
pared by suspending 9.95 mg of glimepiride in 1.94 ml 
aqua bidest., subsequent supplementation of 60/zl of 1 
M NaOH and warming up to 50-70°C. This solution 
was either added directly (up to 1 : 200 dilution) to the 
buffered assay mixtures containing membranes or cells. 
Radiolabeled sulfonylureas were diluted with 25 mM 
Hepes-KOH (pH 7.8). Scintillation cocktail ACS II was 
provided by Amersham-Buchler, Braunschweig, Ger- 
many. Collagenase, trypsin a d proteinase inhibitors 
were from Boehringer, Mannheim, Germany. BSA 
(fraction V, radioimmunoassay grade), RPMI-1640 
medium, fetal calf serum and antibiotics were obtained 
from Sigma, Deisenhofen, Germany. All other reagents 
(analytical grade) were provided from Merck, Darm- 
stadt, Germany. Petri dishes and culture flasks were 
purchased from Nunc, Roskilde, Denmark. Glass fiber 
filters were from Whatman, Maidstone, UK. Nitro- 
cellulose filters were bought from Millipore, Eschborn, 
Germany. Rats of the strain NEDH (New England 
Deaconess Hospital) were kindly donated by S. War- 
ren. 
Cell culture. RINm5F cells of the insulin-producing 
cell line, derived from a rat islet cell tumor [22,23], 
were grown in RPMI-1640 medium containing 10% 
(v/v) heat-inactivated f tal calf serum, 50 IU/ml peni- 
cillin, 0.25 /xg/ml fungizone and 50 ixg/ml strepto- 
mycin at 37°C in an atmosphere of humified air/CO 2 
(19:1) according to Praz et al. [24] with the following 
modifications: The cells were seeded at a density of 
(2-4)" 104 cells/ml in 20 ml of medium (75 cm 2 cul- 
ture flasks). The medium was replaced four times per 
week (one passage). Thereafter, the cells were treated 
with trypsin (0.02% trypsin in 0.9% NaC1/0.2 mM 
EDTA) for 2-5 min at 37°C. The trypsin-treated cells 
were diluted, reseeded at a density of 2" 10 6 cells per 
75 cm 2 culture flask and grown to 70% confluency. 
Preparation of RINmSF cell membranes. Cells from 
one culture flask were washed twice with ice-cold 25 
mM Hepes-KOH (pH 7.4), 0.25 M sucrose, 0.5 mM 
EDTA, scraped with 20 ml of the same buffer and 
homogenized with 10 strokes of a tight fitting Potter- 
Elvehjem homogenizer followed by sonication (bath 
sonicator, 4°C, 10 s, maximal power). After centrifuga- 
tion (200000 ×g, 45 min, 4°C), the pellet was sus- 
pended in 10 ml of 25 mM Hepes-KOH (pH 7.4), 0.25 
M sucrose, 100 mM NaC1, 0.5 mM EDTA, 200 /xM 
PMSF and recentrifuged (1000 x g, 10 min). The su- 
pernatant was transferred to a new tube and cen- 
trifuged (50000 x g, 30 min, 4°C). The pellet was 
washed once with 25 mM Hepes-KOH (pH 7.4), 0.25 
M sucrose and finally suspended in membrane buffer 
(25 mM Hepes-KOH (pH 7.4), 0.25 M sucrose, 150 
mM NaC1, 1 mM EDTA, 100 /.LM PMSF, 10 /xg/ml 
soybean trypsin inhibitor, 10 /xM leupeptin, 10 /xM 
pepstatin, 20 /xg/ml E-64, 1 mM iodoacetamide) at 5 
mg protein/ml. Aliquots were frozen in liquid N 2 and 
stored at - 80°C. 
Preparation of fl-cell tumor membranes. Non-malig- 
nant fl-cell adenoma tissue was dissected from rats of 
the strain NEDH after several transplantation cycles of 
the insulinoma when the tumor has grown up to a 
diameter of 2-3 cm as described previously (Geisen et 
al. [13]), homogenized in 50 ml of buffer A (25 mM 
Hepes-KOH (pH 7.4), 0.25 M sucrose, 0.5 mM EDTA, 
100 ~M PMSF) per g tissue in an Ultraturrax (3 × 5 s, 
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max. power, on ice) and centrifuged (3000 × g, 5 min). 
The supernatant was transferred into new tubes and 
centrifuged (200000 ×g,  60 min, 4°C). The pellet was 
washed with 2 × 5 ml of buffer A, resuspended in 10 
ml of buffer A per g tissue and centrifuged (75 000 × g, 
30 min). The pellet was suspended in buffer A using a 
tight-fitting Dounce homogenizer. 
Binding of sulfonylureas to [3-cell membranes. Filter 
binding assays were performed in a total volume of 1 
ml containing the indicated amounts of protein, 25 mM 
Mops-KOH (pH 7.4), 0.1 mM CaC12 and 0.1-20 nM 
[3H]sulfonylurea. After incubation (25°C, 60 min for 
equilibrium conditions or periods indicated for kinetic 
experiments), the binding reactions were terminated by 
rapid filtration through Whatman GF/F  filters soaked 
in the same buffer. The filters were washed with 3 × 5 
ml of ice-cold 25 mM Hepes-KOH (pH 7.4), 100 mM 
NaCI, 1 mM EDTA, 200 /zM PMSF, 0.5 /zg/ml leu- 
peptin, 0.75/zg/ml pepstatin and 2 × 5 ml of ice-cold 
Hepes-KOH (pH 7.4), placed in 10 ml of ACSII scintil- 
lation cocktail and after incubation overnight counted 
for radioactivity in a liquid scintillation counter. Non- 
specific binding in parallel samples was determined in 
the presence of 1 /zM unlabeled ligand. 
Binding of sulfonylureas to solubilized [3-cell mem- 
brane proteins. Isolated /3-cell tumor or RINm5F cell 
membranes were diluted with 25 mM Mops-KOH (pH 
7.4), 100 mM NaC1, 0.1 mM CaCI 2, 200 ~zM PMSF, 0.5 
/zg/ml leupeptin, 0.75 /xg/ml pepstatin, 50 /xg/ml 
antipain dihydrochloride, 1 /zg/ml aprotinin at 1 mg 
protein/ml and solubilized by addition of 1/10 vol. of 
10% digitonin and subsequent incubation (30 min, 4°C) 
under gentle stirring. After centrifugation (200000 × g, 
30 min, 4°C), indicated amounts of protein contained 
in the supernatant were incubated with radiolabeled 
ligand in a final volume of 1 ml (as described above). 
The binding reactions were terminated by the addition 
of 3 ml of ice-cold 15% PEG 8000, 25 mM Mops-KOH 
(pH 7.4), 100 mM NaCI, 0.5 mM EDTA, 200 /zM 
PMSF. After further incubation (15 min, 4°C), the 
mixtures were filtered through nitrocellulose filters 
(Millipore, HAWP, 0.22/xm) soaked with ice-cold 10% 
PEG 8000. The filters were washed successively with 5 
ml ice-cold 10% PEG 8000 and 4× 5 ml 2% PEG 
8000, dried, placed in 10 ml of ACSII scintillation 
cocktail and counted for radioactivity. Background ra- 
dioactivity, which was measured by filtration of binding 
reactions lacking protein and accounted for up to 0.1% 
of the total radioactivity added, was subtracted from 
the total dpm values. Non-specific binding was deter- 
mined in the presence of 1 /zM unlabeled ligand. 
Binding of sulfonylureas to RINm5F cells. Cells 
seeded in 75 ml culture flasks at a density of 2.106 
cells and grown to 70% confluency were treated with 
t rypsin/EDTA (see above), washed with 3 × 10 ml 
Hepes-based Krebs-Ringer buffer containing 20 mM 
Hepes-KOH (pH 7.4), 125 mM NaCI, 5 mM KC1, 7.5 
mM NaHCO 3, 2 mM CaCl 2, 0.8 mM MgSO 4 sus- 
pended at a density of 2-107 cells/ml in the same 
buffer and then incubated (4°C, 60 min for equilibrium 
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Fig. 1. Scatchard plot analysis of [3H]glimepiride and 
[3H]glibenclamide binding. 100/~g of fl-cell tumor membranes (Panel 
A) or 200 ~g of RINm5F cell membranes (Panel B) or 1.5-10 6 
RINm5F cells (Panel C) were incubated (60 min, 25°C for mem- 
branes or 4°C for cells) with 0.1-20 nM [3H]glimepiride (+) or 
[3H]glibenclamide (D) in the absence (total binding) or presence 
(non-specific binding) of 2 ~M unlabeled glimepiride and gliben- 
clamide, respectively, and then rapidly filtered. Specific glimepiride- 
and glibenclamide-binding was determined by subtracting non- 
specific binding from total binding. The means of at least 12 inde- 
pendent determinations using three different membrane (cell) prepa- 
rations were used for calculation ofthe Scatchard plots. The parame- 
ters of the Scatchard analysis are given i Table 1. 
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binding or periods indicated for kinetic studies) with 
0.1-20 nM [3H]glimepiride or [3H]glibenclamide at a 
density of 4.106 cells per 0.5 ml assay volume. The 
incubation mixtures were rapidly filtered through 
Whatman GF/C  filters soaked in ice-cold buffer under 
reduced pressure. Filtration and washing took less than 
30 s. The filters were washed with 3 × 6 ml of ice-cold 
buffer containing 100/zM PMSF, 0.5/~g/ml leupeptin, 
0.75 /xg/ml pepstatin, 1 /zg/ml aprotinin, 50 /zg an- 
tipain dihydrochloride, 20 /xg/ml E-64, dried, placed 
in 10 ml of ACSII scintillation cocktail and counted for 
radioactivity. Non-specific binding was determined in 
the presence of 1/xM unlabeled ligand. 
Kinetic studies. For studying the association kinetics, 
the binding reactions (incubation conditions see above) 
were started by addition of radiolabeled ligand and 
terminated after the indicated periods by rapid filtra- 
tion. For studying the dissociation kinetics, displace- 
ments of radiolabeled ligand bound at equilibrium (60 
min incubation) were initiated by addition of unlabeled 
drug (final concn. 1 IzM) and terminated after the 
indicated periods. For termination, the incubation mix- 
tures were rapidly chilled to 2-4°C by placing the assay 
tubes in a solid CO2/methanol bath for 1 s immedi- 
ately prior to filtration in a filtration apparatus located 
in a cooled bench. 
Miscellaneous. Protein was determined with the 
Amido black staining method (Popov et al. [25]) using 
BSA as standard. 
3. Results 
3.1. Glimepiride exhibits lower binding affi ity to el-cell 
membranes than glibenclamide 
Specific binding of sulfonylurea drugs to isolated 
/3-cell tumor membranes, HIT T15 and RINm5F cell 
membranes has been attributed to high (K d = 0.1-1 
nM) and low (K a = 100-400 nM) affinity binding sites 
[5,6,13-15,17,19,26,27]. The free plasma glibenclamide 
levels effective in insulin secretion (low nanomolar 
range) and the drug concentration required for half- 
maximal stimulation of insulin release (~ 0.5 nM) from 
pancreatic islets [16] and insulin-secreting cell lines 
[5,14] point to the high-affinity binding site as the only 
functional receptor, the occupancy of which ultimately 
leads to insulin secretion. The difference in the hypo- 
Table 1 
Summary of sulfonylurea receptor binding data 
Parameter Source of receptor Solub. Glimepiride Glibenclamide 
(value _+ S.E.) (value _+ S.E.) 
K d (nM) 
K d (nM) 
Bma x (pmol/mg) 
kof f (min -1) 
kof f (min- 1) 
kon(min ~nM 1) 
kon (min - I  nM -1) 
kofr/ko. (nM) 
koff/kon (nM) 
IC50 glib. (nM) 
K i glib. (nM) 
IC5o glim. (nM) 
K i glim. (nM) 
IC50 glim. (nM) 
K d (nM) 
Bma x (pmol/mg) 
kof f (min- l) 
kon (rain 1 nM- l )  
koff/kon (nM) 
IC50 glib. (nM) 
K i glib. (nM) 
ICs0 glim. (nM) 
K i glim. (nM) 
IC50 glim. (nM) 
K d (nM) 
Bma x (pmol/4 • 106 cells) 
kof f (min- 1) 
kon (min I nM-1) 
koff/kon (nM) 
B-cell tumor memb. 
)-cell tumor memb. + 
8-cell tumor memb. 
t3-cell tumor memb. 
B-cell tumor memb. + 
B-cell tumor memb. 
}-cell tumor memb. + 
~-cell tumor memb. 
B-cell tumor memb. + 
B-cell tumor memb. 
B-cell tumor memb. 
B-cell tumor memb. 
B-cell tumor memb. 
B-cell tumor memb. + 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. 
RINm5F cell memb. + 
RINm5F cells 
RINm5F cells 
RINm5F cells 
RINm5F cells 
RINm5F cells 
1.5 0.3 0.5 0.1 
0.6 0.1 0.5 0.3 
2.3 0.7 2.4 0.8 
3.30 0.28 0.38 0.06 
0.75 0.10 0.32 0.08 
1.78 0.34 0.86 0.09 
1.28 0.43 0.82 0.21 
1.9 0.5 0.4 0.2 
0.6 0.1 0.4 0.1 
40.3 4.1 12.1 3.0 
8.1 1.7 2.4 0.6 
15.5 3.5 5.2 0.8 
6.6 1.1 2.3 0.7 
7.1 0.6 5.1 1.7 
6.8 1.2 2.7 0.3 
1.5 0.4 1.3 0.3 
2.14 0.41 0.25 0.09 
0.49 0.14 0.17 0.08 
4.4 1.2 1.5 0.3 
89.5 54.3 26.7 9.8 
51.4 28.3 15.3 4.3 
31.6 12.6 10.3 8.9 
24.4 9.7 8.0 2.5 
8.2 2.5 7.5 1.3 
4.7 1.0 1.7 0.5 
11.0 1.3 9.4 2.7 
3.61 0.73 0.43 0.11 
0.64 0.21 0.22 0.07 
5.6 2.1 2.0 0.5 
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glycemic efficacy between glimepiride and gliben- 
clamide prompted us to study its binding affinity to 
isolated membranes from /3-cell tumors and RINm5F 
cells as well as to RINm5F cells by equilibrium binding 
using a filtration assay. 
Specific binding of [3H]glimepiride and [3H]gliben- 
clamide to/3-cell tumor and RINm5F cell membranes 
at room temperature ached equilibrium within 50-60 
min (see below) and was protein-dependent (0.05-0.3 
mg /3-cell tumor membrane protein per ml or 0.1-0.5 
mg RINm5F cell membrane protein) in a linear fashion 
(data not shown). Specific binding of [3H]-glimepiride 
and [3H]glibenclamide to RINm5F cells at 4°C was 
dependent on the cell number ((0.2-5)" 10 6 cells/ml). 
Thus, 0.1-0.2 mg protein/ml and 1.5.10 6 cells/ml 
used in the present study were well within the linear 
range of the binding curves. Specific binding of [3H]- 
glimepiride and [3H]glibenclamide to 100/zg of/3-cell 
tumor and 200/zg of RINm5F cell membrane protein 
at room temperature or to 1.5.10 6 RINm5F cells at 
4°C increased from 0.1 to 10 nM radioligand and 
exhibited saturability (data not shown). Displacement 
of [3H]glimepiride- and [3H]glibenclamide-binding with 
excess of the corresponding unlabeled compound re- 
vealed a moderate rise of non-specific binding with 
increasing ligand concentration which, however, never 
exceeded 20% (membranes) and 30% (RINm5F cells) 
of the specific binding. Glimepiride and glibenclamide 
are characterized by comparable non-specific binding 
to/3-cell membranes as well as to RINm5F cells. 
Scatchard plots derived from saturation experiments 
were curve-linear suggesting the existence of both high- 
and low-affinity binding sites in /3-cell tumor mem- 
branes, RINm5F cell membranes and RINm5F cells 
(Fig. 1, Panels A-C). The K d values calculated under 
steady state conditions for the high-affinity binding 
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Fig. 2. Displacement of [3H]glimepiride and [3H]glibenclamide binding to /3-cell membranes by sulfonylurea drugs. 100 ~g of /3-cell tumor 
(Panels A and B) or 200/~g of RINm5F cell membranes (Panels C and D) were incubated (45 min, 25°C) with 2 nM [3H]glimepiride (Panels A 
and C) or [3H]glibenclamide (Panels B and D) in the presence of the indicated concentrations of unlabeled isplacing drug (*, glibenclamide; +, 
glimepiride; t2, tolbutamide) (total binding) or of 2 /zM unlabeled glimepiride and glibenclamide, respectively, (non-specific binding). The 
membranes were filtered and counted for radioactivity. Specific binding (dpm) was calculated as difference between total and non-specific 
binding. Each point represents he mean of 10 different determinations u ing two independent membrane preparations. The IC50 and K i values 
for homologous and heterologous inhibiton of [3H]glimepiride and [3H]glibenclamide binding are given in Table 1. 
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sites are given in Table 1. Thus, glimepiride is charac- 
terized by a 2.5-3-fold lower affinity to rat fl-cell 
tumor and R INm5F cell membranes as well as R INm5F 
cells compared to glibenclamide. The number of high- 
affinity binding sites is very similar for glimepiride and 
glibenclamide, but about 3-4-fold higher for B-cell 
tumor membranes compared to R INmSF membranes 
and R INm5F ceils (Table 1). 
3.2. Displacement of ligand binding confirms the ranking 
order of affinity for glimepiride and glibenclamide 
To confirm the difference in affinity between 
glimepiride and glibenclamide, competition binding ex- 
periments were performed. Displacement curves of 
[3H]glimepiride- and [3H]glibenclamide-binding (Fig. 
2) were used to calculate the concentrations for half- 
maximal inhibition (IC50 values) (Table 1). As expected 
from the lower affinity of glimepiride, this drug was 
less potent in displacing bound [3H]glimepiride (Panels 
A and C) and [3H]glibenclamide (Panels B and D) 
from fl-cell tumor (Panels A and B) and R INmSF 
(Panels C and D) cell membranes than glibenclamide. 
3.5-4-Fold higher concentrations of glimepiride and 
about 1000-fold higher concentrations of tolbutamide 
were necessary to achieve half-maximal inhibition of 
binding. This relationship emphasizes the specificity of 
sulfonylurea binding to fl-cell membranes. 
B-cell tumor membranes 
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Fig. 3. Association kinetics of [3H]sulfonylurea binding to/~-cell membranes and/3-cells. 100 p.g of/3-cell tumor membranes (Panels A and B) or 
200/~g of RINm5F cell membranes (Panel C) or 1.5.10 6 RINm5F cells (Panel D) were incubated (various periods, 25°C for membranes or 4°C 
for cells) with 2 nM [3H]glimepiride (+, *) and [3H]glibenclamide (t2, e) in the absence (total binding) or presence (non-specific binding) of 2 
/.~M unlabeled glimepiride (*) and glibenclamide (e), immediately chilled to 0°C and then rapidly filtered. Specific glimepiride (+) and 
glibenclamide ([]) binding was calculated by subtracting non-specific binding from total binding. The amou t ofradiolabeled sulfonylurea bound 
to RINm5F cells after 60 rain of incubation (equilibrium conditions) was set at 100% (Panel D). Each point represents the mean _+ S.D. of 15 (8) 
different determinations using 5 (4) independent membrane (cell) preparations. Panel B displays the logarithmic plots of the ratio of 
[3Hlglimepiride (+) or [3H]glibenclamide ([]) bound under quilibrium conditions after 45 rain incubation (b(e)) to the difference between the 
sulfonylurea bound at equilibrium (b(e)) and at any time point during incubation (b(t)) versus incubation time (t). The calculated association 
rate constants (kon values) are given in Table 1. 
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3.3. Glimepiride xhibits higher exchange rates for bind- 
ing to B-cell membranes than glibenclamide 
Next we asked the question whether the reduced 
affinity of glimepiride is based on lower association 
and/or  higher dissociation rates of binding compared 
to glibenclamide. For studying the association kinetics 
(Fig. 3), B-cell tumor membranes, R INmSF cell mem- 
branes and R INmSF cells were incubated with 
[3H]glimepiride and [3H]glibenclamide and, after the 
periods indicated, immediately chilled, filtered and 
counted for radioactivity. For studying the dissociation 
kinetics (Fig. 4), the membranes and cells were 
preloaded with submaximal concentrations of [3H] 
sulfonylureas for 60 min at 25°C and 4°C, respectively. 
Displacement of radiolabel was initiated by addition of 
1000-fold molar excess of unlabelel igand. [3H]Glime- 
piride or [3H]glibenclamide r maining bound after the 
indicated periods was determined by rapid filtration. 
The time-courses revealed that glimepiride clearly 
associated with (Fig. 3) and dissociated from (Fig. 4) 
B-cell tumor cell membranes (Panel A), R INmSF cell 
membranes (Panel C) and R INmSF cells (Panel D) 
more rapidly than glibenclamide (half-life times for 
association 2.5-3 min vs. 6-10 min; half-life times for 
dissociation 2-2.5 min vs. 10-14 min) with only 
marginal differences between B-cell tumor mem- 
branes, R INm5F cell membranes and R INm5F cells. 
We studied whether the higher exchange rate of 
glimepiride as revealed by the binding kinetics can 
B-cel l  tumor  membranes  
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Fig. 4. Dissociation kinetics of [3H]sulfonylurea binding to/3-cell membranes and B-cells. 100 ~g of/3-cell tumor membranes (Panels A and B) 
or 200 ~g of RINm5F cell membranes (Panel C) or 1.5.106 RINm5F cells (Panel D) were incubated (45 min, 25°C for membranes or 4°C for 
cells) with 2 nM [3H]glimepiride (+, ) or [3H]glibenclamide ([3, *) in the absence (total binding) or presence (non-specific binding) of 2 ~M 
unlabeled sulfonylurea. At zero time, dissociation was induced by addition of unlabeled glimepiride and glibenclamide (final conch. 2 izM), 
respectively, toone half of each sample (D, +). The other half was left and incubated in parallel as a control (e, *). After the time periods 
indicated, aliquots were immediately chilled, filtered and counted for radioactivity. Specific binding calculated as difference between the total 
and non-specific binding is given as percentage of specific binding at zero time (= 100%). Each point represents the mean :L S.D. of 12 (9) 
independent determinations using 4 (3) different membrane (cell) preparations. Panel B displays the logarithmic plot fthe ratio of sulfonylurea 
bound at any time point (b(t)) to bound at equilibrium (b(e)) versus incubation time (t). The calculated dissociation rateconstants (kof f values) 
are given in Table 1. 
274 G. Miiller et al. /Biochimica et Biophysica Acta 1191 (1994) 267-277 
account for its higher dissociation constant compared 
to glibenclamide as measured by equilibrium binding. 
For this, the K d values were calculated as ratio be- 
tween the dissociation and association rate constants. 
For calculation of the kon rate, the association reaction 
was treated as being pseudo-first order. Fig. 3, Panel B 
displays the logarithmic plots of the ratio of ligand 
concentration bound to /3-cell tumor membranes (not 
shown for RINm5F cell membranes and RINm5F cells) 
under equilibrium conditions to the difference of the 
ligand concentration bound under equilibrium condi- 
tions and bound at each time point (t) versus time. Fig. 
4, Panel B displays the koff rates as the logarithmic 
plot of the ratio of ligand concentration bound at time 
(t) to that bound initially under equilibrium conditions 
versus time (not shown for RINm5F cell membranes 
and RINm5F cells). As expected from the respective 
half-life times, 2.5-3-fold higher association and 7-9- 
fold higher dissociation velocities were calculated for 
glimepiride compared to glibenclamide. The koff/kon 
ratios (Table 1) of glimepiride and glibenclamide for 
binding to fl-cell tumor membranes, RINm5F cell 
membranes and RINm5F cells are well in line with 
their K a values as determined by equilibrium binding. 
Thus, the lower binding affinity of glimepiride is ex- 
plained by its binding kinetics. The logarithmic associa- 
tion and dissociation plots displayed non-linear curves. 
The biphasic nature of the time-courses which was 
more pronounced for glimepiride than for gliben- 
clamide points to the occurrence of either heteroge- 
nous (high- and low-affinity) sulfonylurea binding sites 
or to cooperativity between two (or more) similar bind- 
ing sites rather than to a bimolecular reaction involving 
only one type of binding centre (see Weiland et al. [28] 
for a discussion of binding kinetics). 
3.4. Solubilization of [3-cell membranes alters the binding 
characteristics of the glimepiride-binding sites 
So far it is unknown from which side of the /3-cell 
plasma membrane sulfonylureas gain access to their 
high-affinity binding sites and whether the drugs inter- 
act with the receptor from the aqueous environment or
from the lipid bilayer after lateral movement in the 
plane of the membrane. The accessibility of the recep- 
tor for sulfonylureas may determine in part their bind- 
ing characteristics and explain differences herein be- 
tween drugs of different lipophilicity as is the case for 
glimepiride and glibenclamide. Therefore, we finally 
studied the influence of the membrane environment on 
the K d values and kinetic binding parameters of 
glimepiride and glibenclamide. To allow measurement 
of specific [3H]sulfonylurea binding to detergent- 
solubilized membrane proteins, the filtration assay was 
modified by precipitation of the total incubation mix- 
tures with PEG in the cold prior to filtration over 
solubil ized f~-cell tumor membranes a 
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Fig. 5. Scatchard plot analysis of [3H]sulfonylurea binding to solubi- 
lized/3-cell tumor membrane proteins. The experiments were  carried 
out as described in the legend to Fig. 1 but using 100 ~g of 
digitonin-solubilized/3-cell tumor membrane proteins and precipita- 
tion of the solubilized proteins with poly(ethylene glycol) prior filtra- 
tion. Panel A, saturation curves of specific binding; Panel B, 
Scatchard plot analysis. 
nitrocellulose filters. The precipitates retained on the 
filter were washed with ice-cold PEG-containing wash- 
ing solution. The protein dependence of specific 
[3H]glimepiride and [3H]glibenclamide binding to solu- 
bilized /3-cell tumor membrane proteins, comparable 
maximal binding capacities before and after solubiliza- 
tion and low (15-20%) unspecific binding (data not 
shown) demonstrated almost quantitative recovery of 
[3H]sulfonylurea specifically bound to solubilized/3-cell 
tumor membrane proteins using the modified proce- 
dure. In contrast to/3-cell tumor membranes, RINm5F 
cell membranes and RINm5F cells, low-affinity binding 
sites for both sulfonylureas were barely detectable upon 
solubilization of /3-cell tumor membranes. Similar ob- 
servations were made previously by Niki et al. [29] for 
HIT T15 cell membranes. 
The Scatchard plot analysis hows that solubilization 
by digitonin did only marginally affect the binding 
parameters for glibenclamide (Fig. 5 compared to Fig. 
1). In contrast, glimepiride xhibited a2.5-3-fold higher 
affinity to solubilized fl-cell tumor membrane proteins 
compared to membranes. This was also reflected in the 
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g d values calculated as koff/kon ratios from associa- 
tion and dissociation experiments (Table 1). This rise 
in affinity upon solubilization was based mainly on the 
~ 4.5-fold reduction of the kof rate constant for 
glimepiride (Fig. 6, Panels A and B) whereas the kon 
rate constant decreased only ~ 0.7-fold (Fig. 6, Panels 
C and D) compared to the value for membranes. In 
marked contrast, the kof and kon ra te  constants for 
glibenclamide were only marginally affected upon solu- 
bilization of /3-cell membranes (Fig. 6 and Table 1). 
Consequently, the affinity of glimepiride to solubilized 
/3-cell membranes was only slightly lower than of 
glibenclamide. This was corroborated by the lower 
concentrations of glimepiride but not of glibenclamide 
which were required for displacement of [3H]glime- 
piride bound to solubilized /3-cell tumor (Fig. 7, Panel 
A) and RINmSF cell (Panel B) membrane proteins 
compared to the respective membranes ( ee Fig. 2). As 
a result, the ICs0 values of glimepiride for inhibition of 
[3H]glimepiride binding to the solubilized receptor de- 
creased up to the values of glibenclamide for the 
solubilized as well as membrane-embedded r ceptor 
(Table 1). 
4. D iscuss ion  
The present data strongly suggest hat the lower 
binding affinity of glimepiride to //-cell membranes 
relies at least in part on the membrane nvironment of 
the sulfonylurea receptor. However, this does not ex- 
clude the possibility that glimepiride and glibenclamide 
actually bind to different receptor proteins which dis- 
play different binding characteristics when embedded 
within the fl-cell membrane. Elucidation of this point 
will require identification of the binding proteins, e.g., 
by means of photoaffinity labeling (Kramer et al. [30]; 
see accompanying paper [31]). 
The physiological relevance of the higher exchange 
rate (i.e., higher association and dissociation velocities) 
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Fig. 6. Association and dissociation kinetics of [3H]sulfonylurea binding to solubilized fl-cell tumor membrane proteins. The experiments were 
carried out as described in the legends to Figs. 4 and 5 but using 100/xg of digitonin-solubilized/3-cell tumor membranes and precipitation of the 
solubilized proteins prior to filtration. Panel A, dissociation curves of specific binding; Panel B, logarithmic plots of the dissociation reactions; 
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Fig. 7. Displacement of [3H]glimepiride binding to solubilized/3-cell 
membrane proteins by sulfonylurea drugs. The experiments were 
carried out as described in the legend to Fig. 2 but using 100 ~g of 
solubilized B-cell tumor (Panel A) or 200/xg of RINm5F cell (Panel 
B) membrane proteins, respectively, and precipitation of the solubi- 
lized proteins with poly(ethylene glycol) prior to filtration. 
of glimepiride with its receptor protein as well as of its 
lower binding affinity compared to glibenclamide r - 
mains a matter of speculation. (i) The initial decrease 
of the blood sugar levels in dogs, rats and rabbits is 
more pronounced after oral and intravenous adminis- 
tration of clear sodium salt solutions of glimepiride 
compared to, glibenclamide [21]. The rapid-onset blood 
glucose lowering activity of glimepiride may be due to a 
more rapid direct insulinotropic effect upon the islet of 
Langerhans. In agreement with this hypothesis, it was 
found that in the perifused rat pancreatic slets and in 
the isolated perfused rat pancreas, glimepiride re- 
leased insulin more rapidly and more effectively than 
glibenclamide (Geisen, K., unpublished results). This 
may be related to the 3-fold higher kon rate of 
glimepiride binding to /3-cell membranes. However, 
with respect o the blood sugar lowering profile, it is 
difficult o dissect differences in kinetic binding param- 
eters from different pharmacokinetic behaviour of the 
two drugs. (ii) The prolonged ecline of plasma glucose 
levels provoked by a single oral dose of glimepiride 
compared to glibenclamide in dogs and rabbits (Geisen 
[21]) may be explained by the 3-fold higher exchange 
rate of glimepiride bound to the sulfonylurea receptor 
if desensitization f the insulin releasing mechanism is 
induced by occupancy of the sulfonylurea receptor with 
a drug (exhibiting a lower exchange rate). Desensitiza- 
tion of receptor mediated processes by permanent 
binding of the ligand to its receptor involving distinct 
molecular mechanisms i  well established for several 
hormone signaling pathways, i.e., /3-adrenergic recep- 
tors (for a review, see Benovic et al. [32]). In this 
respect, it is interesting that internalization of gliben- 
clamide has been reported for HIT T15 cells (Carpen- 
tier et ah [33]). If this based on endocytosis of the 
sulfonylurea receptor when occupied by the ligand, it 
may represent a mechanism for desensitization by down 
regulation of the number of sulfonylurea receptors at 
the cell surface which will be more pronounced for 
sulfonylureas with lower exchange rate. However, the 
long term hypoglycemic activity of sulfonylureas, in
general, and of glimepiride, in special, may involve 
so-called extra-pancreatic sites of action, in addition 
(Kolterman et al. [34]; Mi]ller et ah [35]; for a review, 
see Gerich [36]). (iii) The higher K d value of glime- 
piride compared to glibenclamide may be responsible 
for the lower total decline of the blood sugar in the dog 
(Geisen [21]). Clearly, these features would represent 
significant therapeutical benefits for NIDDM patients. 
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